[ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].

Gavrilova SI, Kolykhalov IV, Korovaĭtseva GI, Zharikov GA, Kalyn IaB, Selezneva ND

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2005Cited by 3 (Europe PMC)

PMID15880838PepBankPUB-15880838

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In mild-moderate Alzheimer's disease, Cerebrolysin produced a higher and more stable clinical effect than exelon.
In plain wordsIn patients with Alzheimer's disease, Cerebrolysin produced a greater and more stable clinical effect than exelon.
Peptide
Cerebrolysin
Outcome
IncreaseClinical effect
Study
n: not reported in source
Comparator
exelon
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated · 4-monthAs given in this study (human).
Source sentences
Summary
A 4-month treatment has shown that both types of therapy had a significant clinical effect, however clinical effect proved to be more higher and stable in patients treated with cerebrolysin.
1 context sentence(design, population, supporting numbers)
Summary · context
Correlation association between an ApoE4 genotype in patients with mild-moderate Alzheimer's disease and efficacy of neurotrophic (cerebrolysin) and cholinergic (exelon) therapy was studied in the groups of patients formed using case-control method.
Report a problemFND-1588083801
02HumanObservational studyEfficacy outcome
In mild-moderate Alzheimer's disease, the number of responders was 1.7-fold higher with Cerebrolysin than with exelon.
In plain wordsIn patients with Alzheimer's disease, Cerebrolysin had more responders than exelon.
Peptide
Cerebrolysin
Outcome
IncreaseResponders
Study
n: not reported in source
Comparator
exelon
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated · 4-monthAs given in this study (human).
Measurements
Responder number ratio
1.7 fold
Cerebrolysin versus exelon
Source sentences
Summary
A number of responders in the cerebrolysin group was 1.7-fold higher comparing to that in the exelon group.
1 context sentence(design, population, supporting numbers)
Summary · context
Correlation association between an ApoE4 genotype in patients with mild-moderate Alzheimer's disease and efficacy of neurotrophic (cerebrolysin) and cholinergic (exelon) therapy was studied in the groups of patients formed using case-control method.
Report a problemFND-1588083802
03HumanObservational studyEfficacy outcome
In ApoE4(+) patients with Alzheimer's disease, response did not differ between Cerebrolysin and exelon.
In plain wordsIn ApoE4(+) patients with Alzheimer's disease, response did not differ between Cerebrolysin and exelon.
Peptide
Cerebrolysin
Outcome
No significant changeResponse in ApoE4(+) patients
Study
n: not reported in source
Comparator
exelon
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated · 4-monthAs given in this study (human).
Source sentences
Summary
Patients with the ApoE4(+) genotype did not differ in response to either drug
1 context sentence(design, population, supporting numbers)
Summary · context
Correlation association between an ApoE4 genotype in patients with mild-moderate Alzheimer's disease and efficacy of neurotrophic (cerebrolysin) and cholinergic (exelon) therapy was studied in the groups of patients formed using case-control method.
Report a problemFND-1588083803
04HumanObservational studyEfficacy outcome
In ApoE4(-) patients with Alzheimer's disease, the number of responders was 3-fold higher with Cerebrolysin than with exelon.
In plain wordsIn ApoE4(-) patients with Alzheimer's disease, Cerebrolysin had more responders than exelon.
Peptide
Cerebrolysin
Outcome
IncreaseResponders in ApoE4(-) patients
Study
n: not reported in source
Comparator
exelon
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated · 4-monthAs given in this study (human).
Measurements
Responder number ratio
3 fold
ApoE4(-)
Source sentences
Summary
but in those with genotype ApoE4(-) the number of responders was 3-fold higher in the group treated with cerebrolysin compared to the group given exelon.
1 context sentence(design, population, supporting numbers)
Summary · context
Correlation association between an ApoE4 genotype in patients with mild-moderate Alzheimer's disease and efficacy of neurotrophic (cerebrolysin) and cholinergic (exelon) therapy was studied in the groups of patients formed using case-control method.
Report a problemFND-1588083804
05HumanObservational studyEfficacy outcome
In ApoE4(-) patients, the long-term clinical effect of Cerebrolysin was 6.5 times higher than that of exelon.
In plain wordsIn ApoE4(-) patients, Cerebrolysin had a greater long-term clinical effect than exelon.
Peptide
Cerebrolysin
Outcome
IncreaseLong-term clinical effect in ApoE4(-) patients
Study
n: not reported in source
Comparator
exelon
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Clinical effect ratio
6.5 times
Cerebrolysin versus exelon
Source sentences
Summary
A follow-up estimation of cognitive impairment in ApoE4(-) patients revealed that long-term clinical effect of cerebrolysin treatment was 6.5 times higher than that of exelon.
1 context sentence(design, population, supporting numbers)
Summary · context
Correlation association between an ApoE4 genotype in patients with mild-moderate Alzheimer's disease and efficacy of neurotrophic (cerebrolysin) and cholinergic (exelon) therapy was studied in the groups of patients formed using case-control method.
Report a problemFND-1588083805
06HumanObservational studyEfficacy outcome
In mild-moderate Alzheimer's disease, Cerebrolysin treatment had a significant clinical effect over 4 months, as did exelon treatment.
In plain wordsIn Alzheimer's disease patients, both Cerebrolysin and exelon treatment showed significant clinical effects during treatment.
Peptide
Cerebrolysin
Outcome
IncreaseClinical effect during treatment
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated · 4-monthAs given in this study (human).
Source sentences
Summary
A 4-month treatment has shown that both types of therapy had a significant clinical effect, however clinical effect proved to be more higher and stable in patients treated with cerebrolysin.
1 context sentence(design, population, supporting numbers)
Summary · context
Correlation association between an ApoE4 genotype in patients with mild-moderate Alzheimer's disease and efficacy of neurotrophic (cerebrolysin) and cholinergic (exelon) therapy was studied in the groups of patients formed using case-control method.
Report a problemFND-1588083806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.